Hiv candidates into clinical trials. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy4

Cell Line, Tumor CD4-Positive T-Lymphocytes Cell Line Cells, Cultured

Organisms1

Diseases24

HIV Infections HIV Seropositivity Neoplasms Acquired Immunodeficiency Syndrome Disease Progression Breast Neoplasms Recurrence Substance Abuse, Intravenous AIDS-Related Opportunistic Infections Stroke Disease Models, Animal Genetic Predisposition to Disease Lung Neoplasms Acute Disease Chronic Disease Coinfection Substance-Related Disorders Drug-Related Side Effects and Adverse Reactions Pain Prostatic Neoplasms HIV Enteropathy Cardiovascular Diseases Tuberculosis Diabetes Mellitus, Type 2

Chemicals and Drugs32

Anti-HIV Agents Placebos Antineoplastic Agents HIV Antigens HIV Protease Inhibitors Anti-Retroviral Agents HIV Core Protein p24 Biological Markers HIV Reverse Transcriptase Drugs, Investigational HIV Envelope Protein gp120 Antibodies, Monoclonal HIV Protease Receptors, HIV Drug Combinations Recombinant Proteins Antiviral Agents Antibodies, Monoclonal, Humanized RNA, Viral Vaccines, Synthetic Zidovudine Vaccines, Attenuated Genetic Markers HIV Envelope Protein gp41 Tumor Markers, Biological Anti-Bacterial Agents Vaginal Creams, Foams, and Jellies Malaria Vaccines Anti-Infective Agents, Local Cancer Vaccines Organophosphonates HIV Fusion Inhibitors

Analytical, Diagnostic and Therapeutic Techniques and Equipment106

Clinical Trials as Topic Clinical Trials, Phase III as Topic Clinical Trials, Phase II as Topic Treatment Outcome Clinical Trials, Phase I as Topic Research Design Double-Blind Method Controlled Clinical Trials as Topic HIV Seroprevalence Patient Selection Randomized Controlled Trials as Topic Prospective Studies Multicenter Studies as Topic Placebos Follow-Up Studies Clinical Trials, Phase IV as Topic Clinical Protocols Risk Factors Single-Blind Method AIDS Serodiagnosis Drug Therapy, Combination Early Termination of Clinical Trials Pilot Projects Drug Administration Schedule CD4 Lymphocyte Count Sample Size Questionnaires Reproducibility of Results Severity of Illness Index Viral Load Survival Analysis Combined Modality Therapy Cohort Studies Antineoplastic Combined Chemotherapy Protocols Administration, Oral Endpoint Determination Risk Assessment Prevalence Prognosis Feasibility Studies Retrospective Studies Data Interpretation, Statistical Survival Rate Drug Evaluation, Preclinical Incidence Gene Expression Profiling Disease-Free Survival Cross-Sectional Studies Drug Evaluation Sensitivity and Specificity Chromosome Mapping Pain Measurement Analysis of Variance Cross-Over Studies Meta-Analysis as Topic Mass Screening Therapeutic Human Experimentation Multivariate Analysis Predictive Value of Tests Drug Approval Random Allocation Condoms Disease Models, Animal Treatment Failure Logistic Models Exercise Therapy Models, Statistical Kaplan-Meier Estimate Drug Design Phytotherapy Cluster Analysis Statistics, Nonparametric Infusions, Intravenous Case-Control Studies Regression Analysis Drug Discovery Program Evaluation Immunotherapy Sequence Analysis, DNA Polymerase Chain Reaction Proportional Hazards Models Genetic Therapy Molecular Targeted Therapy Chi-Square Distribution Odds Ratio Longitudinal Studies Chemotherapy, Adjuvant Data Collection Neoplasm Staging Vaccination Oligonucleotide Array Sequence Analysis Interviews as Topic Genetic Association Studies Vaginal Creams, Foams, and Jellies Administration, Intravaginal Models, Biological Human Experimentation Risk Enzyme-Linked Immunosorbent Assay Chemoprevention Circumcision, Male Statistics as Topic Reverse Transcriptase Polymerase Chain Reaction Control Groups Probability Drug Delivery Systems

Psychiatry and Psychology16

Sexual Behavior Patient Compliance Homosexuality, Male Counseling Risk-Taking Health Knowledge, Attitudes, Practice Substance Abuse, Intravenous Risk Reduction Behavior Unsafe Sex Cognitive Therapy Substance-Related Disorders Pain Motivation Safe Sex Prostitution Decision Making

Phenomena and Processes31

HIV Seronegativity Time Factors CD4 Lymphocyte Count Viral Load Dose-Response Relationship, Drug Homosexuality, Male Pregnancy Genotype Polymorphism, Single Nucleotide Sensitivity and Specificity Algorithms Mutation Amino Acid Sequence Phenotype Genetic Predisposition to Disease Base Sequence Virus Replication Genetic Vectors Quantitative Trait Loci Pain Chi-Square Distribution Odds Ratio Genetic Markers Genetic Linkage Risk Signal Transduction Drug Resistance, Viral Alleles Genetic Variation Haplotypes Probability

Disciplines and Occupations10

Research Design Outcome Assessment (Health Care)Evidence-Based Medicine Biomedical Research Medical Oncology Therapeutic Human Experimentation Drug Design Drug Discovery Human Experimentation Statistics as Topic

Anthropology, Education, Sociology and Social Phenomena11

Quality of Life Informed Consent Drug Approval Patient Education as Topic United States Food and Drug Administration National Institutes of Health (U.S.)Health Education National Cancer Institute (U.S.)Prostitution International Cooperation Developing Countries

Technology, Industry, Agriculture2

Dietary Supplements Drug Industry

Humanities2

Quality of Life Ethics Committees, Research

Information Science13

Questionnaires Molecular Sequence Data Prevalence Data Interpretation, Statistical Survival Rate Incidence Algorithms Amino Acid Sequence Base Sequence Internet Publishing Data Collection Interviews as Topic

Named Groups6

Research Subjects Sexual Partners Infant, Newborn Patient Dropouts HIV Long-Term Survivors African Americans

Health Care87

Clinical Trials as Topic Clinical Trials, Phase III as Topic Clinical Trials, Phase II as Topic Treatment Outcome Clinical Trials, Phase I as Topic Double-Blind Method Controlled Clinical Trials as Topic HIV Seroprevalence Patient Selection Randomized Controlled Trials as Topic Prospective Studies Multicenter Studies as Topic Follow-Up Studies Clinical Trials Data Monitoring Committees Clinical Trials, Phase IV as Topic Clinical Protocols Risk Factors Single-Blind Method Early Termination of Clinical Trials Pilot Projects Sample Size Questionnaires Reproducibility of Results Severity of Illness Index Cost-Benefit Analysis Patient Compliance Outcome Assessment (Health Care)Survival Analysis Cohort Studies Counseling Risk Assessment Health Knowledge, Attitudes, Practice Prevalence Informed Consent Feasibility Studies Retrospective Studies Data Interpretation, Statistical Survival Rate Incidence Placebo Effect Patient Participation Disease-Free Survival Cross-Sectional Studies Sensitivity and Specificity Analysis of Variance Cross-Over Studies Meta-Analysis as Topic Mass Screening Multivariate Analysis Predictive Value of Tests Age Factors Random Allocation Patient Education as Topic Treatment Failure Logistic Models Intention to Treat Analysis United States Food and Drug Administration Models, Statistical Kaplan-Meier Estimate Practice Guidelines as Topic Cluster Analysis Patient Acceptance of Health Care Guidelines as Topic Patient Satisfaction Statistics, Nonparametric Bias (Epidemiology)Case-Control Studies Regression Analysis Program Evaluation National Institutes of Health (U.S.)Proportional Hazards Models Research Support as Topic Chi-Square Distribution Odds Ratio Longitudinal Studies Health Education Data Collection Vaccination Interviews as Topic National Cancer Institute (U.S.)Safety Risk Voluntary Programs Health Care Costs Ethics Committees, Research Statistics as Topic Probability

Geographicals14

United States South Africa Uganda Zimbabwe Africa South of the Sahara Malawi India Europe Great Britain Zambia China Africa Kenya Tanzania

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Technology, Industry, Agriculture Humanities Information Science Named Groups Health Care Geographicals

Clinical Trials as Topic HIV Infections HIV Seropositivity Clinical Trials, Phase III as Topic Clinical Trials, Phase II as Topic Treatment Outcome Clinical Trials, Phase I as Topic Research Design Double-Blind Method Controlled Clinical Trials as Topic HIV Seroprevalence HIV Seronegativity Patient Selection Randomized Controlled Trials as Topic Time Factors HIV-1 Prospective Studies Multicenter Studies as Topic Anti-HIV Agents Placebos Follow-Up Studies Neoplasms Clinical Trials Data Monitoring Committees Clinical Trials, Phase IV as Topic Clinical Protocols Acquired Immunodeficiency Syndrome Risk Factors United States Antineoplastic Agents Single-Blind Method HIV Antigens AIDS Serodiagnosis Drug Therapy, Combination Early Termination of Clinical Trials HIV Protease Inhibitors Pilot Projects Drug Administration Schedule CD4 Lymphocyte Count Sexual Behavior Sample Size Questionnaires Quality of Life Reproducibility of Results Research Subjects Severity of Illness Index Cost-Benefit Analysis Anti-Retroviral Agents Viral Load Disease Progression Molecular Sequence Data Dose-Response Relationship, Drug Patient Compliance Outcome Assessment (Health Care)Homosexuality, Male Survival Analysis Combined Modality Therapy Cohort Studies South Africa Antineoplastic Combined Chemotherapy Protocols Administration, Oral Counseling Evidence-Based Medicine Endpoint Determination Risk-Taking Risk Assessment Health Knowledge, Attitudes, Practice Prevalence Pregnancy Informed Consent Prognosis HIV Core Protein p24 Breast Neoplasms Biological Markers Biomedical Research HIV Reverse Transcriptase Genotype Drugs, Investigational Feasibility Studies Retrospective Studies HIV Envelope Protein gp120 Data Interpretation, Statistical Recurrence Polymorphism, Single Nucleotide Sexual Partners Survival Rate Drug Evaluation, Preclinical Incidence Placebo Effect Antibodies, Monoclonal HIV Protease Substance Abuse, Intravenous Gene Expression Profiling Uganda Patient Participation Dietary Supplements Receptors, HIV Disease-Free Survival Cross-Sectional Studies Drug Evaluation Sensitivity and Specificity

No FAQ available that match "hiv candidates into clinical trials"